The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.
For more information or questions about a study, email email@example.com or call 312-355-5112.
S1933: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status
Sponsor: National Cancer Institute
Principal Investigator: Lawrence Feldman, MD